MedTrace Logo

Study With CIN-107 Following Multiple Oral Ascending Doses in Healthy Subjects

NCT05500820 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2023-08-14

No results posted yet for this study

Summary

This is a randomized, double-blind, study to assess the safety, tolerability, PK, and PD of multiple oral doses of CIN-107 when administered to healthy adult subjects.

Conditions

Interventions

DRUG

CIN-107

A repeat oral dose of CIN-107 once daily for 10 days.

DRUG

Matching Placebo

A repeat oral dose of matching placebo once daily for 10 days.

Sponsors & Collaborators

Principal Investigators

  • Leela Vrishabhendra, MD · Medpace Clinical Pharmacology Unit

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-19
Primary Completion
2020-04-03
Completion
2020-04-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05500820 on ClinicalTrials.gov